Kunyuan Cui

Title: Kunyuan Cui: Innovator in Nucleic Acid Technologies

Introduction

Kunyuan Cui is a notable inventor based in Bothell, WA (US), recognized for his contributions to the field of nucleic acid technologies. With a total of 6 patents to his name, Cui has made significant advancements that have implications in therapeutic applications.

Latest Patents

Cui's latest patents include innovative technologies such as "Long interfering nucleic acid duplexes targeting multiple RNA targets." This patent describes long interfering nucleic acid (iNA) duplexes that are at least 30 nucleotides in length, featuring at least one nick or nucleotide gap in the strands. These duplexes do not induce an interferon response when transfected into mammalian cells, allowing for targeted therapy without unwanted immune reactions. Another significant patent is for "Lipomacrocycles and uses thereof," which details macrocyclic compounds formed by the reaction of a cyclic compound containing an amine with an epoxide. These compounds enhance the delivery of therapeutic molecules in lipid systems, making them compatible with liposomes and lipid particles.

Career Highlights

Throughout his career, Kunyuan Cui has worked with several prominent companies, including Marina Biotech, Inc. and Agave Pharma, Incorporated. His work in these organizations has contributed to the development of innovative solutions in biotechnology and pharmaceuticals.

Collaborations

Cui has collaborated with notable colleagues such as Dong Liang and Lishan Chen, further enhancing the impact of his research and inventions.

Conclusion

Kunyuan Cui's work in nucleic acid technologies showcases his innovative spirit and dedication to advancing therapeutic methods. His patents reflect a commitment to improving medical treatments and highlight his role as a significant contributor to the field.